Baldry Mark 4
4 · X4 Pharmaceuticals, Inc · Filed Oct 8, 2024
Insider Transaction Report
Form 4
Baldry Mark
Chief Commercial Officer
Transactions
- Sale
Common Stock
2024-10-07$0.58/sh−11,127$6,506→ 48,509 total - Award
Common Stock
2024-10-04+34,946→ 59,636 total
Footnotes (3)
- [F1]Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition.
- [F2]These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.561 to $0.6115, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.